Cabaletta Bio, Inc. (CABA)
| Market Cap | 573.94M +783.6% |
| Revenue (ttm) | n/a |
| Net Income | -167.86M |
| EPS | -2.10 |
| Shares Out | 163.05M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,559,255 |
| Open | 3.530 |
| Previous Close | 3.590 |
| Day's Range | 3.320 - 3.550 |
| 52-Week Range | 1.260 - 4.230 |
| Beta | 3.17 |
| Analysts | Strong Buy |
| Price Target | 14.50 (+311.93%) |
| Earnings Date | May 14, 2026 |
About CABA
Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with autoimmune diseases. The company’s lead product candidate is resecabtagene autoleucel, a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T, which is in Phase 1/2 clinical trials for the treatment of dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, juvenile myositis, lupus nephritis, systemic lupus erythematosus, relapsing and progressive multiple sclero... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 6 analysts, the average rating for CABA stock is "Strong Buy." The 12-month stock price target is $14.5, which is an increase of 311.93% from the latest price.
News
Cabaletta Bio presents new clinical data for rese-cel
Cabaletta Bio (CABA) announced new clinical and translational data from the first four patients in the lowest dose cohort in RESET-PV evaluating preconditioning-free rese-cel and initial manufacturing...
Cabaletta Bio reports Q1 EPS (39c), consensus (39c)
“Since January, while advancing our myositis pivotal trial and planning to initiate a second pivotal indication, we announced that we have signed a long-term commercial supply agreement with Cellares ...
Cabaletta Bio Reports First Quarter 2026 Financial Results and Provides Business Update
Preconditioning-free (PC-free) 6-to-9-month clinical data with a single infusion of the lowest dose of rese-cel in the RESET-PV ® study presented today at ASGCT 2026 Annual Meeting along with initial ...
Cabaletta Bio Presents Preconditioning-free Clinical Data and Automated Manufacturing Translational Data for Rese-cel at ASGCT 2026 Annual Meeting
A single infusion of the lowest dose of rese-cel administered without preconditioning, after discontinuation of all immunomodulators, demonstrated compelling drug-free responses for 6 months in 2 of 4...
Cabaletta Bio financing overhang concerns should be addressed, says Cantor
Cabaletta Bio (CABA) provided updates for CABA-201, saying that two out of four pemphigus vulgaris patients treated with CABA-201 without preconditioning chemo achieved virtually complete and durable ...
Cabaletta Bio Announces Pricing of $150 Million Underwritten Offering
PHILADELPHIA, May 04, 2026 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (“Cabaletta” or the “Company”) (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching curative ta...
Cabaletta Bio, Cellares report 10-year commercial supply agreement for rese-cel
Cabaletta Bio (CABA) and Cellares announced a commercial agreement to supply resecabtagene autoleucel using Cellares’ automated Cell Shuttle and through future implementation of Cellares’ Cell Q platf...
Cabaletta Bio, Cellares enter 10-year commercial agreement
Cabaletta Bio (CABA) and Cellares announced a commercial agreement to supply rese-cel using Cellares’ automated Cell Shuttle and through future implementation of Cellares’ Cell Q platform. The Compani...
Cabaletta Bio and Cellares Announce 10-Year Commercial Supply Agreement for Rese-cel
Agreement facilitates flexible, scalable automated industrialized production of rese-cel for many thousands of patients per year at a cost per batch that is among the lowest in the industry Initial t...
Cellares and Cabaletta Bio Sign 10-Year Commercial Supply Agreement to Scale Rese-cel
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cellares, the first Integrated Development and Manufacturing Organization (IDMO), today announced it has entered into a 10-year commercial supply agreemen...
Cabaletta Bio Announces Multiple Upcoming Presentations, Including Data on Rese-cel without Preconditioning and Rese-cel with Automated Manufacturing, at the ASGCT 2026 Annual Meeting
PHILADELPHIA, April 27, 2026 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a late-stage clinical biotechnology company focused on developing and launching targeted cell therapies designed sp...
Patients dosed with Cabaletta’s rese-cel manufactured on Cellares’ Cell Shuttle
Cellares announced that Cabaletta Bio (CABA) Inc.’s investigational CAR T cell therapy rese-cel has been infused into the first two patients using drug product manufactured on Cellares’ Cell Shuttle a...
First Patients Dosed with Cabaletta Bio's Rese-cel Manufactured on Cellares' Automated Cell Shuttle™ Platform
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cellares, the first Integrated Development and Manufacturing Organization (IDMO), today announced that Cabaletta Bio Inc.'s (“Cabaletta Bio” or “Cabaletta...
Morgan Stanley and Jefferies Analysts Forecast Over 350% Upside Potential for Cabaletta Bio Stock
Cabaletta Bio ($CABA) is emerging as a top pick for Wall Street’s biggest banks following its latest financial update on Monday, March 23, 2026. Both Morgan Stanley ($MS) and Jefferies…
Cabaletta Bio price target lowered to $13 from $14 at Morgan Stanley
Morgan Stanley lowered the firm’s price target on Cabaletta Bio (CABA) to $13 from $14 and keeps an Overweight rating on the shares. Rese-cel execution remains on track with data…
Cabaletta Bio price target raised to $16 from $15 at Guggenheim
Guggenheim raised the firm’s price target on Cabaletta Bio (CABA) to $16 from $15 and keeps a Buy rating on the shares after the company reported Q4 results and said…
Cabaletta Bio reports Q4 EPS (40c), consensus (47c)
As of December 31, 2025, Cabaletta had cash, cash equivalents and short-term investments of $133.6M, compared to $164M as of December 31, 2024. “As we advance our core clinical programs…
Cabaletta Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Rese-cel myositis BLA submission on track for 2027 based on a 17-patient, single arm registrational cohort design, including an outpatient dosing option
Cabaletta Bio Transcript: TD Cowen 46th Annual Health Care Conference
Key clinical milestones include pivotal myositis trial enrollment, upcoming durability data in pemphigus and lupus, and phase I/II results in multiple autoimmune indications. Automated manufacturing with Cellares enables scalable, cost-effective production, while a favorable safety profile and no preconditioning regimen could transform market adoption.
Cabaletta Bio to Participate in the TD Cowen 46th Annual Health Care Conference
PHILADELPHIA, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a late-stage clinical biotechnology company focused on developing and launching the first curative targeted cell the...
Cabaletta Bio Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026
The summit highlighted progress in pivotal myositis trials, advances in automated manufacturing, and a strong safety profile enabling outpatient treatment. Regulatory alignment supports single-arm trials, and the commercial model leverages automation for scalability and cost efficiency.
Cabaletta Bio to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
PHILADELPHIA, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a late-stage clinical biotechnology company focused on developing and launching the first curative targeted cell the...
Cabaletta Bio participates in a conference call with William Blair
Conference call with management to be held on February 10 at 3 pm hosted by William Blair.
Largest borrow rate increases among liquid names
Latest data shows the largest indicative borrow rate increases among liquid option names include: Cabaletta Bio (CABA) 4.23% +1.87, Tradr 2X Long IREN Daily ETF (IREX) 23.52% +1.55, Li Auto…
Cabaletta Bio announces 2026 strategic priorities
Translate registrational pathways with rese-cel into a pipeline in a product across autoimmune diseases Initiation of myositis registrational cohort: Cabaletta initiated the U.S. Food and Drug Adminis...